INT35609

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1983
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 37
Total Number 37
Disease Relevance 17.15
Pain Relevance 4.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (F10) extracellular region (F10) plasma membrane (F10)
Anatomy Link Frequency
plasma 6
platelet 2
bridge 1
F10 (Homo sapiens)
Pain Link Frequency Relevance Heat
Angina 20 99.08 Very High Very High Very High
cva 824 99.00 Very High Very High Very High
anesthesia 5 94.80 High High
analgesia 3 94.58 High High
aspirin 94 94.00 High High
Bioavailability 69 92.16 High High
Pain 12 91.76 High High
antagonist 141 91.40 High High
peripheral neuropathy 2 90.72 High High
carpal tunnel syndrome 2 87.36 High High
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 15 99.84 Very High Very High Very High
Disease 46 99.40 Very High Very High Very High
Cv General 3 Under Development 347 99.08 Very High Very High Very High
Thrombosis Related Under Development 411 98.92 Very High Very High Very High
Coagulation Disorder 60 97.96 Very High Very High Very High
Cancer 17 96.96 Very High Very High Very High
Amyloidosis 42 96.88 Very High Very High Very High
Heparin-induced Thrombocytopenia 66 96.68 Very High Very High Very High
Myocardial Infarction 116 96.12 Very High Very High Very High
Frailty 26 96.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In unstable angina patients, plasma levels of TF, TFPI and TFPI/FXa were more efficiently reduced by adjunct ticlopidine therapy compared with adjunct coumadin/dipyridamole.
Negative_regulation (reduced) of FXa in plasma associated with angina
1) Confidence 0.57 Published 2003 Journal Blood Coagul. Fibrinolysis Section Abstract Doc Link 12945880 Disease Relevance 0.39 Pain Relevance 0.45
Enoxaparin is a low-molecular-weight heparin (LMWH) derivative that exerts its anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa.
Negative_regulation (inhibitor) of factor Xa
2) Confidence 0.57 Published 2007 Journal Expert Rev Cardiovasc Ther Section Abstract Doc Link 17489664 Disease Relevance 0.24 Pain Relevance 0.05
Fondaparinux, a pentasaccharide, is a synthetic indirect inhibitor of Factor Xa (FXa).
Negative_regulation (inhibitor) of FXa
3) Confidence 0.46 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2879296 Disease Relevance 1.01 Pain Relevance 0.03
In the design of new antithrombotic drugs it therefore seems attractive to target the mode of action towards inhibition of FXa.
Negative_regulation (inhibition) of FXa
4) Confidence 0.40 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0
Fondaparinux is a synthetic pentasaccharide with the same mode of action as UFH and LMWH, but in contrast to those it acts solely by the antithrombin-mediated inhibition of FXa (Samama and Gerotziafas 2003).
Negative_regulation (inhibition) of FXa
5) Confidence 0.40 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0
A dose-dependent prolongation of PT, activated partial thromboplastin time (aPTT), and HepTest to a similar extent to inhibition of FXa were seen, and it was suggested that the inhibition of the FXa activity of rivaroxaban can be monitored by these clotting tests or by measurement of FXa alone (Kubitza 2005a).
Negative_regulation (inhibition) of FXa associated with coagulation disorder
6) Confidence 0.40 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0.38 Pain Relevance 0.06
A dose-dependent prolongation of PT, activated partial thromboplastin time (aPTT), and HepTest to a similar extent to inhibition of FXa were seen, and it was suggested that the inhibition of the FXa activity of rivaroxaban can be monitored by these clotting tests or by measurement of FXa alone (Kubitza 2005a).
Negative_regulation (inhibition) of FXa associated with coagulation disorder
7) Confidence 0.40 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0.32 Pain Relevance 0.12
Unlike heparin, fondaparinux does not inactivate thrombin or inhibit FXa bound in the prothrombinase complex and therefore does not completely inhibit FXa.
Negative_regulation (inhibit) of FXa
8) Confidence 0.34 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2879296 Disease Relevance 0.98 Pain Relevance 0.06
Unlike heparin, fondaparinux does not inactivate thrombin or inhibit FXa bound in the prothrombinase complex and therefore does not completely inhibit FXa.
Negative_regulation (inhibit) of FXa
9) Confidence 0.34 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2879296 Disease Relevance 0.94 Pain Relevance 0.03
Rivaroxaban – an oral, direct FXa inhibitor – is a new compound for VTE prophylaxis after orthopedic surgery.
Negative_regulation (inhibitor) of FXa associated with cva
10) Confidence 0.34 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0.43 Pain Relevance 0.13
In vitro studies have shown that rivaroxaban can inhibit both free FXa and FXa bound in the prothrombinase complex more potently in human and rabbit plasma than in rat plasma.
Negative_regulation (inhibit) of FXa in plasma
11) Confidence 0.34 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0.22 Pain Relevance 0.05
As a consequence the direct FXa inhibitors are able to inhibit both free FXa and FXa bound in the prothrombinase complex (Perzborn 2005) (Figure 1).
Negative_regulation (inhibit) of FXa
12) Confidence 0.34 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0.03
Besides dabigatran etexilate these agents are rivaroxaban, apixaban, and edoxaban, all of which inhibit FXa.
Negative_regulation (inhibit) of FXa
13) Confidence 0.30 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2879296 Disease Relevance 0 Pain Relevance 0
FXa inhibition appears to be the more promising avenue, as Factor X has fewer functions outside coagulation compared with thrombin.
Negative_regulation (inhibition) of FXa
14) Confidence 0.30 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2879296 Disease Relevance 0.25 Pain Relevance 0.06
Unfractionated heparin (UFH) and LMWH are indirect FXa inhibitors because they inhibit FXa by potentiation of the natural inhibitory action of antithrombin (AT) that is an endogeneous plasma protein.
Negative_regulation (inhibit) of FXa in plasma
15) Confidence 0.29 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0
Rivaroxaban belongs to a new group of oral direct FXa inhibitors.
Negative_regulation (inhibitors) of FXa
16) Confidence 0.29 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0.04
Unfractionated heparin (UFH) and LMWH are indirect FXa inhibitors because they inhibit FXa by potentiation of the natural inhibitory action of antithrombin (AT) that is an endogeneous plasma protein.
Negative_regulation (inhibitors) of FXa in plasma
17) Confidence 0.29 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0
The study showed a dose-dependent inhibition of FXa and an additional prolongation of prothrombin time (PT), which correlated with the plasma concentration of rivaroxaban.
Negative_regulation (inhibition) of FXa in plasma
18) Confidence 0.29 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0.39 Pain Relevance 0.03
As a consequence the direct FXa inhibitors are able to inhibit both free FXa and FXa bound in the prothrombinase complex (Perzborn 2005) (Figure 1).
Negative_regulation (inhibitors) of FXa
19) Confidence 0.29 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0.03
On the contrary, direct FXa inhibitors, including rivaroxaban, do not need AT to exert their inhibitory action on FXa, because they are able to bind directly to the active site of FXa, thereby preventing interaction with its substrates.
Negative_regulation (inhibitors) of FXa
20) Confidence 0.29 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox